Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any early infantile epileptic encephalopathy in which the cause of the disease is a mutation in the EEF1A2 gene.
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:32 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Features include always present findings: Bilateral tonic-clonic seizure, Incoordination, Hypsarrhythmia, and Absent speech and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 12 | Bilateral tonic-clonic seizure, Absent speech, Delayed speech and language development |
Muscles | 2 | Low muscle tone (hypotonia), Neonatal hypotonia |
Head and neck | 1 | Secondary microcephaly |
Pregnancy and birth | 1 | Neonatal hypotonia |
Age of onset: newborn period.
EEF1A2 encodes eukaryotic translation elongation factor 1 alpha 2 (463 aa). Translation elongation factor that catalyzes the GTP-dependent binding of aminoacyl-tRNA (aa-tRNA) to the A-site of ribosomes during the elongation phase of protein synthesis. Highest expression in Muscle Skeletal (2,328 TPM) and Brain Cerebellar Hemisphere (972.2 TPM).
Developmental and epileptic encephalopathy, 33 is associated with mutations in the EEF1A2 gene on chromosome 20.
EEF1A2 is classified as a druggable target with score 26.1.
Genetic testing for EEF1A2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for developmental and epileptic encephalopathy, 33 has been reported in the published literature.
Phenotype severity distribution: 17 always present features.
No clinical trials have been registered for developmental and epileptic encephalopathy, 33.
87 publications have been identified in PubMed for developmental and epileptic encephalopathy, 33. Research spans Epidemiology / Natural History (41%), Review / Meta-Analysis (16%), and Clinical Trial Publication (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 36 | 41% |
Research summaries | 14 | 16% |
Clinical study results | 13 | 15% |
Laboratory research | 8 | 9% |
Patient case studies | 7 | 8% |
Testing and diagnosis research | 4 | 5% |
New treatment approaches | 4 | 5% |
Other research | 1 | 1% |
Miles JT (2026). [PMID: 41389010](https://pubmed.ncbi.nlm.nih.gov/41389010/). *J Neurophysiol*. [Epidemiology / Natural History]
Coppola A (2026). [PMID: 41558068](https://pubmed.ncbi.nlm.nih.gov/41558068/). *Epilepsy Res*. [Review / Meta-Analysis]
Tan M (2026). [PMID: 41642117](https://pubmed.ncbi.nlm.nih.gov/41642117/). *Epilepsia*. [Basic Science / Preclinical]
Fasaludeen A (2026). [PMID: 41619470](https://pubmed.ncbi.nlm.nih.gov/41619470/). *Pediatr Neurol*. [Epidemiology / Natural History]
Lea TA (2026). [PMID: 41380247](https://pubmed.ncbi.nlm.nih.gov/41380247/). *Epilepsy Behav*. [Clinical Trial Publication]
Galassi Deforie V (2026). [PMID: 41860019](https://pubmed.ncbi.nlm.nih.gov/41860019/). *Genet Med*. [Basic Science / Preclinical]
Balestrini S (2026). [PMID: 41137852](https://pubmed.ncbi.nlm.nih.gov/41137852/). *Epilepsia*. [Epidemiology / Natural History]
Sun XL (2026). [PMID: 42039691](https://pubmed.ncbi.nlm.nih.gov/42039691/). *Drug Des Devel Ther*. [Epidemiology / Natural History]
Lee ST (2026). [PMID: 41863185](https://pubmed.ncbi.nlm.nih.gov/41863185/). *Neurotherapeutics*. [Epidemiology / Natural History]
Biagioni T (2026). [PMID: 41663195](https://pubmed.ncbi.nlm.nih.gov/41663195/). *Arch Dis Child Fetal Neonatal Ed*. [Diagnostic / Biomarker]